{
  "ptid_time": "007_S_4467_2012-04-27",
  "img_path": "/data/qiuhui/data/adni/images/007_S_4467/2012-04-27/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 12,720 mm³, 43.1% below the reference mean. With a Z-score of -1.08 (14.1th percentile), this represents mild atrophy; whole brain volume measures 1,031,600 mm³, 0.2% above the reference mean. With a Z-score of 0.03 (51.2th percentile), this represents normal volume ; entorhinal cortex volume measures 3,237 mm³, 16.8% below the reference mean. With a Z-score of -1.31 (9.6th percentile), this represents mild atrophy; fusiform gyrus volume measures 19,458 mm³, 6.9% above the reference mean. With a Z-score of 0.77 (78.0th percentile), this represents normal volume ; middle temporal gyrus volume measures 18,739 mm³, 8.7% below the reference mean. With a Z-score of -0.77 (22.0th percentile), this represents normal volume . ",
  "text_data": "Age is 61.9 years. Gender is Female. Education: 12 years. Handedness: Right. Race: White. Medical history: Psychiatric; Cardiovascular; Musculoskeletal; Gastrointestinal; Allergies or Drug Sensitivities; Smoking; Major Surgical Procedures. MMSE: 27.0. MoCA: 24.0. Logical Memory: 9.0. APOEε4 alleles: 2.0. Biomarker levels: Florbetapir (AV45): 1.40 SUVR (significant elevated); Amyloid beta: 705.20 pg/mL (normal ); Total tau: 675.60 pg/mL (profound elevated); Phosphorylated tau: 76.51 pg/mL (profound elevated). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging shows mild atrophy in the ventricular volume and entorhinal cortex, with normal whole brain, fusiform gyrus, and middle temporal gyrus volumes. Clinically, the patient has normal Aβ but profoundly elevated T-tau and P-tau, along with significant AV45 (amyloid PET) positivity, suggesting underlying Alzheimer's pathology despite normal MMSE and borderline MoCA.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI) due to Alzheimer’s disease** (biomarker-supported).  \n\n**Confidence:** **High** (due to clear biomarker evidence of tauopathy and amyloidosis, along with mild structural and cognitive changes).  \n\n*Note: The presence of two APOE4 alleles further supports Alzheimer's risk, but the diagnosis is primarily driven by the biomarker profile (Aβ-, tau+, neurodegeneration+), fitting the AT(N) framework for Alzheimer's pathology.*",
  "timestamp": "2025-07-25T22:00:49.884412"
}